Lineas de Investigación

01. Psiquiatria Genética: análisis de variables genéticas asociadas a la expresión de fenotipo Bipolar I y II en una cohorte de familias con alta agregación (Dr. F. Mayoral y Dr. J. Guzman)

02. Biomarcadores y Nuevas Dianas Terapéuticas en Trastornos Generales del desarrollo (Dra Yolanda de Diego)

03. Evaluación y aplicación de nuevas tecnologías para un envejecimiento saludable (Dr Mayoral)

04. Epidemiologia y Evaluación de Resultados en Salud Mental (Dra Berta Moreno)



Proyectos de Investigación

TV-based ASSistive Integrated Service to SupporT European adults living with Dementia

COMISIÓN EUROPEA
Unión Europea 2017

Support monitoring and reminder techonology for mild dementia (SMART4MD)

COMISIÓN EUROPEA
Unión Europea 2015

PI16/00647 Evaluación del malestar subjetivo en la esquizofrenia: Viabilidad de la Escala PRE en España. Estudio PRE España

INSTITUTO DE SALUD CARLOS III
ACCIÓN ESTRATÉGICA EN SALUD - PROYECTOS DE INVESTIGACIÓN EN SALUD 2016

RC-0006-2015 Acciones para el refuerzo con recursos humanos de la actividad investigadora en las Unidades de Gestión Clínica del Servicio Andaluz de Salud 2015. Renovación de la acción C (Programa Nicolás Monardes) de la Convocatoria 2012

SERVICIO ANDALUZ DE SALUD
RENOVACIÓN ACCIÓN C (PROGRAMA NICOLÁS MONARDES) DE LA CONVOCATORIA 2015

F. ALICIA KOPLOWITZ-2016-01 Interacción del metabolismo y el ambiente en la aparición y la severidad de los trastornos del espectro autista

FUNDACIÓN ALICIA KOPLOWITZ
AYUDAS A PROYECTOS DE INVESTIGACIÓN 2016

PI-0060-2017 Uso de Una Puntuación Genética de Riesgo para el Trastorno Bipolar: Estudio de Seguimiento A Largo Plazo en Familias de Alto Riesgo.

CONSEJERÍA DE SALUD
PROYECTOS DE INVESTIGACIÓN EN SALUD 2017

PI16/01746 Eficacia de terapia psicológica de baja intensidad con el apoyo de Internet en pacientes con multimorbilidad en el ámbito de atención primaria. Un ensayo clínico controlado

INSTITUTO DE SALUD CARLOS III
ACCIÓN ESTRATÉGICA EN SALUD - PROYECTOS DE INVESTIGACIÓN EN SALUD 2016

Estudios Clínicos

54135419SUI3001. Estudio doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia y la seguridad de la esketamina intranasal, además del tratamiento integral según la práctica habitual, para la reducción rápida de los síntomas del trastorno depresivomay

JANSSEN-CILAG INTERNATIONAL N.V.
Fase: III ENSAYO CLINICO COMERCIAL

54135419TRD3008. Estudio de extensión, abierto, de seguridad a largo plazo de esketamina en la depresión resistente al tratamiento. Seguridad y mantenimiento de la respuesta al tratamiento con esketamina con dosis repetidas en intervalos determinados por la gravedad de lo

JANSSEN-CILAG INTERNATIONAL N.V.
Fase: III ENSAYO CLINICO COMERCIAL


Publicaciones científicas

  • Todo
  • D1
  • Q1
  • Q2
  • Otro
Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multi-center, three-armed randomized controlled trial conducted in primary care.

Romero-Sanchiz P, Nogueira-Arjona R, García-Ruiz A, Luciano JV, García Campayo J, Gili M, Botella C, Baños R, Castro A, López-Del-Hoyo Y, Pérez Ara MÁ, Modrego-Alarcón M, Mayoral Cleríes F.
PLoS One. 2017 Feb 27;12(2):e0172741.

Depression is one of the most common mental disorders and will become one of the leading causes of disability in the world. Internet-based CBT programs for depression have been classified as «well established» following the American Psychological Association criteria for empirically supported treatments. The aim of this study is to analyze the cost effectiveness at 12-month follow-up of the Internet-based CBT program «Smiling is fun» with (LITG) […]

Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia.

Witt SH, Streit F, Jungkunz M, Frank J, Awasthi S, Reinbold CS, Treutlein J, Degenhardt F, Forstner AJ, Heilmann-Heimbach S, Dietl L, Schwarze CE, Schendel D, Strohmaier J, Abdellaoui A, Adolfsson R, Air TM, Akil H, Alda M, Alliey-Rodriguez N, Andreassen OA, Babadjanova G, Bass NJ, Bauer M, Baune BT, Bellivier F, Bergen S, Bethell A, Biernacka JM, Blackwood DHR, Boks MP, Boomsma DI, Børglum AD, Borrmann-Hassenbach M, Brennan P, Budde M, Buttenschøn HN, Byrne EM, Cervantes P, Clarke TK, Craddock N, Cruceanu C, Curtis D, Czerski PM, Dannlowski U, Davis T, de Geus EJC, Di Florio A, Djurovic S, Domenici E, Edenberg HJ, Etain B, Fischer SB, Forty L, Fraser C, Frye MA, Fullerton JM, Gade K, Gershon ES, Giegling I, Gordon SD, Gordon-Smith K, Grabe HJ, Green EK, Greenwood TA, Grigoroiu-Serbanescu M, Guzman-Parra J, Hall LS, Hamshere M, Hauser J, Hautzinger M, Heilbronner U, Herms S, Hitturlingappa S, Hoffmann P, Holmans P, Hottenga JJ, Jamain S, Jones I, Jones LA, Juréus A, Kahn RS, Kammerer-Ciernioch J, Kirov G, Kittel-Schneider S, Kloiber S, Knott SV, Kogevinas M, Landén M, Leber M, Leboyer M, Li QS, Lissowska J, Lucae S, Martin NG, Mayoral-Cleries F, McElroy SL, McIntosh AM, McKay JD, McQuillin A, Medland SE, Middeldorp CM, Milaneschi Y, Mitchell PB, Montgomery GW, Morken G, Mors O, Mühleisen TW, Müller-Myhsok B, Myers RM, Nievergelt CM, Nurnberger JI, O’Donovan MC, Loohuis LMO, Ophoff R, Oruc L, Owen MJ, Paciga SA, Penninx BWJH, Perry A, Pfennig A, Potash JB, Preisig M, Reif A, Rivas F, Rouleau GA, Schofield PR, Schulze TG, Schwarz M, Scott L, Sinnamon GCB, Stahl EA, Strauss J, Turecki G, Van der Auwera S, Vedder H, Vincent JB, Willemsen G, Witt CC, Wray NR, Xi HS; Bipolar Disorders Working Group of the Psychiatric Genomics Consortium; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Tadic A, Dahmen N, Schott BH, Cichon S, Nöthen MM, Ripke S, Mobascher A, Rujescu D, Lieb K, Roepke S, Schmahl C, Bohus M, Rietschel M.
Transl Psychiatry. 2017 Jun 20;7(6):e1155.

Borderline personality disorder (BOR) is determined by environmental and genetic factors, and characterized by affective instability and impulsivity, diagnostic symptoms also observed in manic phases of bipolar disorder (BIP). Up to 20% of BIP patients show comorbidity with BOR. This report describes the first case-control genome-wide association study (GWAS) of BOR, performed in one of the largest BOR patient samples worldwide. The focus of our […]

Identification of shared risk loci and pathways for bipolar disorder and schizophrenia.

Forstner AJ, Hecker J, Hofmann A, Maaser A, Reinbold CS, Mühleisen TW, Leber M, Strohmaier J, Degenhardt F, Treutlein J, Mattheisen M, Schumacher J, Streit F, Meier S, Herms S, Hoffmann P, Lacour A, Witt SH, Reif A, Müller-Myhsok B, Lucae S, Maier W, Schwarz M, Vedder H, Kammerer-Ciernioch J, Pfennig A, Bauer M, Hautzinger M, Moebus S, Schenk LM, Fischer SB, Sivalingam S, Czerski PM, Hauser J, Lissowska J, Szeszenia-Dabrowska N, Brennan P, McKay JD, Wright A, Mitchell PB, Fullerton JM, Schofield PR, Montgomery GW, Medland SE, Gordon SD, Martin NG, Krasnov V, Chuchalin A, Babadjanova G, Pantelejeva G, Abramova LI, Tiganov AS, Polonikov A, Khusnutdinova E, Alda M, Cruceanu C, Rouleau GA, Turecki G, Laprise C, Rivas F, Mayoral F, Kogevinas M, Grigoroiu-Serbanescu M, Becker T, Schulze TG, Rietschel M, Cichon S, Fier H, Nöthen MM.
PLoS One. 2017 Feb 6;12(2):e0171595.

Bipolar disorder (BD) is a highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. BD shows substantial clinical and genetic overlap with other psychiatric disorders, in particular schizophrenia (SCZ). The genes underlying this etiological overlap remain largely unknown. A recent SCZ genome wide association study (GWAS) by the Psychiatric Genomics Consortium identified 128 independent genome-wide sig […]

Randomized control trial to assess the efficacy of metacognitive training compared with a psycho-educational group in people with a recent-onset psychosis.

Ochoa S, López-Carrilero R, Barrigón ML, Pousa E, Barajas A, Lorente-Rovira E, González-Higueras F, Grasa E, Ruiz-Delgado I, Cid J, Birulés I, Esteban-Pinos I, Casañas R, Luengo A, Torres-Hernández P, Corripio I, Montes-Gámez M, Beltran M, De Apraiz A, Domínguez-Sánchez L, Sánchez E, Llacer B, Pélaez T, Bogas JL, Moritz S; Spanish Metacognition Study Group.
Psychol Med. 2017 Jul;47(9):1573-1584.

Aims were to assess the efficacy of metacognitive training (MCT) in people with a recent onset of psychosis in terms of symptoms as a primary outcome and metacognitive variables as a secondary outcome. […]

Use of the ADAPTE Method to Develop a Guideline for the Improvement of Depression Care in Primary Care.

Nogueras EV, Hurtado MM, Flordelís E, García-Herrera JM, Morales-Asencio JM.
Psychiatr Serv. 2017 Aug 1;68(8):759-761.

Depression is the most frequent psychiatric disorder in primary health care, and the evidence shows that there is suboptimal management by primary care practitioners, perhaps owing to difficulties in decision making. Because clinical guidelines can improve decision making and management, a clinical guideline to manage depression in primary health care was developed in adherence to the ADAPTE method and was implemented in the Málaga Primary Healt […]

Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics.

Montejo ÁL, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, Del Pino-Montes J, García-Escudero MA, García-Rizo C, González-Pinto A, Hernández AI, Martín-Carrasco M, Mayoral-Cleries F, Mayoral-van Son J, Mories MT, Pachiarotti I, Pérez J, Ros S, Vieta E.
Front Neuroendocrinol. 2017 Apr;45:25-34.

Hyperprolactinemia is an underappreciated/unknown adverse effects of antipsychotics. The consequences of hyperprolactinemia compromise therapeutic adherence and can be serious. We present the consensus recommendations made by a group of experts regarding the management of antipsychotic-induced hyperprolactinemia. The current consensus was developed in 3 phases: 1, review of the scientific literature; 2, subsequent round table discussion to attemp […]

Patients Admitted to Three Spanish Intensive Care Units for Poisoning: Type of Poisoning, Mortality, and Functioning of Prognostic Scores Commonly Used.

Banderas-Bravo ME, Arias-Verdú MD, Macías-Guarasa I, Aguilar-Alonso E, Castillo-Lorente E, Pérez-Costillas L, Gutierrez-Rodriguez R, Quesada-García G, Rivera-Fernández R.
Biomed Res Int. 2017;2017:5261264.

Objectives. To evaluate the gravity and mortality of those patients admitted to the intensive care unit for poisoning. Also, the applicability and predicted capacity of prognostic scales most frequently used in ICU must be evaluated. Methods. Multicentre study between 2008 and 2013 on all patients admitted for poisoning. Results. The results are from 119 patients. The causes of poisoning were medication, 92 patients (77.3%), caustics, 11 (9.2%), […]

Predictors of repeat visits to hospital psychiatric emergency departments in Malaga (Spain) and in Lisbon (Portugal).

Moreno-Küstner B, Warnke I, Nordt C, Fernandez G, Ramos J, Paulino-Matos P, Rössler W, Cardoso G.
Emerg Med J. 2017 Oct;34(10):665-671.

This study describes the profile of people with mental disorders attending emergency departments (EDs) in two countries and to identify specific mental disorders associated with repeat emergency visits. […]

Gender matters in schizophrenia-spectrum disorders: Results from a healthcare users epidemiological study in Malaga, Spain.

Petkari E, Mayoral F, Moreno-Küstner B.
Compr Psychiatry. 2017 Jan;72:136-143.

Women suffering from schizophrenia-spectrum disorders may differ from men in clinical course and outcome. Still, those differences can only be portrayed accurately by means of studies that derive information from multiple sources. One such study was performed in a well-defined area supported by a Mental Health Clinical Management Unit in Malaga, Spain. […]

Personality traits and psychotic symptoms in recent onset of psychosis patients.

Sevilla-Llewellyn-Jones J, Cano-Domínguez P, de-Luis-Matilla A, Peñuelas-Calvo I, Espina-Eizaguirre A, Moreno-Kustner B, Ochoa S.
Compr Psychiatry. 2017 Apr;74:109-117.

Personality in patients with psychosis, and particularly its relation to psychotic symptoms in recent onset of psychosis (ROP) patients, is understudied. The aims of this research were to study the relation between dimensional and categorical clinical personality traits and symptoms, as well as the effects that symptoms, sex and age have on clinically significant personality traits. […]


An Sist Sanit Navar. 2017 Dec 29;40(3):379-389.

Suicidal behaviour (fatal and non-fatal) has become a serious public health problem in many countries. The aim of the study was to describe the differential characteristics of emergency calls due to suicidal behaviour made to the Emergency Coordinating Centre (CCUE) in the province of Málaga, in comparison with calls due to physical or psychiatric problems. […]

Physical fitness and levels of physical activity in people with severe mental illness: a cross-sectional study.

Perez-Cruzado D, Cuesta-Vargas AI, Vera-Garcia E, Mayoral-Cleries F.
BMC Sports Sci Med Rehabil. 2017 Nov 25;9:17.

Physical fitness is a crucial variable in people with severe mental illness as these people could be more independent and improve their job opportunities. The present study compared the physical fitness of physically active and inactive people with severe mental illness. […]

TV-based assistive integrated service to support European adults living with mild dementia or mild cognitive impairment (TV-AssistDem): study protocol for a multicentre randomized controlled trial.

Goodman-Casanova JM, Guzmán-Parra J, Guerrero G, Vera E, Barnestein-Fonseca P, Cortellessa G, Fracasso F, Umbrico A, Cesta A, Toma D, Boghiu F, Dewarrat R, Triantafyllidou V, Tamburini E, Dionisio P, Mayoral F.
BMC Geriatr. 2019 Sep 6;19(1):247.

Mild cognitive impairment and mild dementia progressively compromise the ability of people to live independently and can have a negative impact on their quality of life. Within the current European Active and Assisted Living programme (AAL), project TV-AssistDem has been developed to deliver a TV-based platform service to support patients with mild cognitive impairment or mild dementia and provide relief to their caregivers. The application is in […]


Subscribe

Suscríbete a nuestro Newsletter y recibe en tu correo todas las últimas novedades del Instituto.
Consulta el histórico de Newsletter:

Calle Doctor Miguel Díaz Recio , 28 Málaga 29010

(+34) 951 440 260
Fax: (+34) 951 440 263